[New oncolytic agents and immunomodulators and their application].
After a long period without change, colorectal oncology has in recent years entered the frontline of progress in cancer treatment and research. Improved diagnostic techniques have brought forward the diagnosis of metastatic disease, enabling potential curative surgery in the case of liver metastases. Due to both the earlier start of systemic treatment and the increase in number of active drugs, survival of patients with metastatic disease has increased to a median of approximately 18 months. Two important cytotoxic drugs, oxaliplatin and irinotecan, have contributed to this progress. Recently, it was demonstrated that addition ofa monoclonal antibody against vascular endothelial growth factor, bevacizumab, led to an increase in survival comparable to the effects of both cytotoxic agents. Increase in survival, as a hallmark for drug efficacy, is an endpoint that patients and the medical community seem to agree on. The financial consequences of these combinations for the hospital budget are considerable, but their share in the total drug economy is still small. Oxaliplatin has also emerged as a useful drug in the adjuvant setting, after surgery for primary colon cancer.